Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Yuan, Cunzhong ^a   Liu, Xiaoyan ^a   Yan, Shi ^a   Wang, Cunfang ^b   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b QILU UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

XRCC3 PROTEIN; DNA BINDING PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3;

CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; HETEROZYGOTE; HOMOZYGOTE; HUMAN; META ANALYSIS (TOPIC); OVARY CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; FEMALE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; OVARY TUMOR; PUBLISHING;

CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS;

EID: 84903640245     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/648137     Document Type: Review

References (42)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012 62 1 10 29 2-s2.0-84855792427 10.3322/caac.20138
2. Risch H. A., Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute 1998 90 23 1774 1786 2-s2.0-0032477328 (Pubitemid 28559889)
3. Meindl A., Hellebrand H., Wiek C., Erven V., Wappenschmidt B., Niederacher D., Freund M., Lichtner P., Hartmann L., Schaal H., Ramser J., Honisch E., Kubisch C., Wichmann H. E., Kast K., Deiler H., Engel C., Müller-Myhsok B., Neveling K., Kiechle M., Mathew C. G., Schindler D., Schmutzler R. K., Hanenberg H., Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Genetics 2010 42 5 410 414 2-s2.0-77951720395 10.1038/ng.569
4. Loveday C., Turnbull C., Ramsay E., Hughes D., Ruark E., Frankum J. R., Bowden G., Kalmyrzaev B., Warren-Perry M., Snape K., Adlard J. W., Barwell J., Berg J., Brady A. F., Brewer C., Brice G., Chapman C., Cook J., Davidson R., Donaldson A., Douglas F., Greenhalgh L., Henderson A., Izatt L., Kumar A., Lalloo F., Miedzybrodzka Z., Morrison P. J., Paterson J., Porteous M., Rogers M. T., Shanley S., Walker L., Eccles D., Evans D. G., Renwick A., Seal S., Lord C. J., Ashworth A., Reis-Filho J. S., Antoniou A. C., Rahman N., Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics 2011 43 9 879 882 2-s2.0-80052264429 10.1038/ng.893
5. Yin J., Lu K., Lin J., Wu L., Hildebrandt M. A. T., Chang D. W., Meyer L., Wu X., Liang D., Genetic variants in TGF- β pathway are associated with ovarian cancer risk. PLoS ONE 2011 6 9 2-s2.0-80053591338 10.1371/journal.pone. 0025559 e25559
6. Ma X., Zhang J., Liu S., Huang Y., Chen B., Wang D., Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer. Gynecologic Oncology 2011 122 3 554 559 2-s2.0-80051552713 10.1016/j.ygyno.2011.05.031
7. Permuth-Wey J., Kim D., Tsai Y.-Y., Lin H.-Y., Chen Y. A., Barnholtz-Sloan J., Birrer M. J., Bloom G., Chanock S. J., Chen Z., Cramer D. W., Cunningham J. M., Dagne G., Ebbert-Syfrett J., Fenstermacher D., Fridley B. L., Garcia-Closas M., Gayther S. A., Ge W., Gentry-Maharaj A., Gonzalez-Bosquet J., Goode E. L., Iversen E., Jim H., Kong W., McLaughlin J., Menon U., Monteiro A. N. A., Narod S. A., Pharoah P. D. P., Phelan C. M., Qu X., Ramus S. J., Risch H., Schildkraut J. M., Song H., Stockwell H., Sutphen R., Terry K. L., Tyrer J., Vierkant R. A., Wentzensen N., Lancaster J. M., Cheng J. Q., Sellers T. A., LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Research 2011 71 11 3896 3903 2-s2.0-79957905172 10.1158/0008-5472.CAN- 10-4167
8. Braem M. G. M., Schouten L. J., Peeters P. H. M., van den Brandt P. A., Onland-Moret N. C., Genetic susceptibility to sporadic ovarian cancer: a systematic review. Biochimica et Biophysica Acta 2011 1816 2 132 146 2-s2.0-79958780982 10.1016/j.bbcan.2011.05.002
9. Pelttari L. M., Heikkinen T., Thompson D., Kallioniemi A., Schleutker J., Holli K., Blomqvist C., Aittomäki K., Bützow R., Nevanlinna H., RAD51C is a susceptibility gene for ovarian cancer. Human Molecular Genetics 2011 20 16 3278 3288 2-s2.0-79960815893 10.1093/hmg/ddr229
10. Ramus S. J., Antoniou A. C., Kuchenbaecker K. B., Soucy P., Beesley J., Chen X., Mcguffog L., Sinilnikova O. M., Healey S., Barrowdale D., Lee A., Thomassen M., Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation 2012 33 4 690 702 2-s2.0-84862792587 10.1002/humu.22025
11. Yuan C., Li X., Yan S., Yang Q., Liu X., Kong B., The MTDH (-470G>A) polymorphism is associated with ovarian cancer susceptibility. PLoS ONE 2012 7 12 2-s2.0-84871107583 10.1371/journal.pone.0051561 e51561
12. Bolton K. L., Tyrer J., Song H., Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics 2010 42 10 880 884 10.1038/ng.666
13. Goode E. L., Chenevix-Trench G., Song H., A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics 2010 42 10 874 879 10.1038/ng.668
14. Song H., Ramus S. J., Tyrer J., A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22. 2. Nature Genetics 2009 41 9 996 1000 10.1038/ng.424
15. Li Y., Zhao H., Sun L., Huang L., Yang Q., Kong B., MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Human Cell 2011 24 2 57 64 2-s2.0-79958028622 10.1007/s13577-011-0013-4
16. Tebbs R. S., Zhao Y., Tucker J. D., Scheerer J. B., Siciliano M. J., Hwang M., Liu N., Legerski R. J., Thompson L. H., Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proceedings of the National Academy of Sciences of the United States of America 1995 92 14 6354 6358 2-s2.0-0029071063 10.1073/pnas.92.14.6354
17. Zhan P., Wang Q., Qian Q., Yu L.-K., XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis. Journal of Experimental & Clinical Cancer Research 2013 32, article 1 2-s2.0-84871724720 10.1186/1756-9966-32-1
18. Zhao B., Ye J., Li B., Ma Q., Su G., Han R., DNA repair gene XRCC3 Thr241Met polymorphism and glioma risk: a meta-analysis. International Journal of Clinical and Experimental Medicine 2013 6 6 438 443 2-s2.0-84879945027
19. Matullo G., Palli D., Peluso M., Guarrera S., Carturan S., Celentano E., Krogh V., Munnia A., Tumino R., Polidoro S., Piazza A., Vineis P., XRCC1, XRCC3, XPD gene polymorphisms, smoking and 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001 22 9 1437 1445 2-s2.0-0034812088 (Pubitemid 32898701)
20. Auranen A., Song H., Waterfall C., DiCioccio R. A., Kuschel B., Kjaer S. K., Hogdall E., Hogdall C., Stratton J., Whittemore A. S., Easton D. F., Ponder B. A. J., Novik K. L., Dunning A. M., Gayther S., Pharoah P. D. P., Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. International Journal of Cancer 2005 117 4 611 618 2-s2.0-27144475439 10.1002/ijc.21047 (Pubitemid 41504549)
21. Yin Q.-H., Liu C., Li L., Zu X.-Y., Wang Y.-J., Association between the XRCC3 T241M polymorphism and head and neck cancer susceptibility: a meta-analysis of case-control studies. Asian Pacific Journal of Cancer Prevention 2012 13 10 5201 5205 2-s2.0-84874006697 10.7314/APJCP.2012.13.10.5201
22. He X.-F., Wei W., Su J., Yang Z.-X., Liu Y., Zhang Y., Ding D.-P., Wang W., Association between the XRCC3 polymorphisms and breast cancer risk: meta-analysis based on case-control studies. Molecular Biology Reports 2012 39 5 5125 5134 2-s2.0-84863754412 10.1007/s11033-011-1308-y
23. Tian X., Tian Y., Ma P., Association between the XRCC3 C241T polymorphism and lung cancer risk in the Asian population. Tumour Biology 2013 34 5 2589 2597
24. He X.-F., Wei W., Li J.-L., Shen X.-L., Ding D.-P., Wang S.-L., Liu Z.-Z., Qin J.-B., Wu L.-X., Xie D.-L., Association between the XRCC3 T241M polymorphism and risk of cancer: evidence from 157 case-control studies. Gene 2013 523 1 10 19 2-s2.0-84877810503 10.1016/j.gene.2013.03.071
25. Quaye L., Tyrer J., Ramus S. J., Song H., Wozniak E., DiCioccio R. A., McGuire V., Høhdall E., Høhdall C., Blaakaer J., Goode E. L., Schildkraut J. M., Easton D. F., Krüger-Kjaer S., Whittemore A. S., Gayther S. A., Pharoah P. D. P., Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. PLoS ONE 2009 4 6 2-s2.0-67650102671 10.1371/journal.pone.0005983 e5983
26. Beesley J., Jordan S. J., Spurdle A. B., Song H., Ramus S. J., Kjaer S. K., Hogdall E., DiCioccio R. A., McGuire V., Whittemore A. S., Gayther S. A., Pharoah P. D. P., Webb P. M., Chenevix-Trench G., Bowtell D., Green A., DeFazio A., Gertig D., Traficante N., Moore S., Hung J., Fereday S., Harrap K., Sadkowsky T., Mellon A., Robertson R., Vanden Bergh T., Maidens J., Nattress K., Chiew Y. E., Stenlake A., Sullivan H., Alexander B., Ashover P., Brown S., Corrish T., Green L., Jackman L., Martin K., Ranieri B., White J., Jayde V., Bowes L., Mamers P., Schmidt T., Shirley H., Viduka S., Tran H., Bilic S., Glavinas L., Proietto A., Braye S., Otton G., Bonaventura T., Stewart J., Friedlander M., Bell D., Baron-Hay S., Ferrier A., Gard G., Nevell D., Young B., Camaris C., Crouch R., Edwards L., Hacker N., Marsden D., Robertson G., Beale P., Beith J., Carter J., Dalrymple C., Hamilton A., Houghton R., Russell P., Brand A., Jaworski R., Harnett P., Wain G., Crandon A., Cummings M., Horwood K., Obermair A., Wyld D., Nicklin J., Perrin L., Ward B., Davy M., Hall C., Dodd T., Healy T., Pittman K., Henderson D., Hyde S., Miller J., Pierdes J., Blomfield P., Challis D., McIntosh R., Parker A., Brown B., Rome R., Allen D., Grant P., Laurie R., Robbie M., Healy D., Jobling T., Maniolitas T., McNealage J., Rogers P., Susil B., Veitch A., Constable J., Tong S. P., Robinson I., Simpson I., Phillips K., Rischin D., Waring P., Loughrey M., O'Callaghan N., Murray B., Billson V., Galloway S., Pyman J., Quinn M., Hammond I., McCartney A., Leung Y., Haviv I., Purdie D., Whiteman D., Zeps N., Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiology Biomarkers and Prevention 2007 16 12 2557 2565 2-s2.0-38849190562 10.1158/1055-9965.EPI-07-0542 (Pubitemid 351196309)
27. Webb P. M., Hopper J. L., Newman B., Chen X., Kelemen L., Giles G. G., Southey M. C., Chenevix-Trench G., Spurdle A. B., Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiology Biomarkers and Prevention 2005 14 2 319 323 2-s2.0-13944270627 10.1158/1055-9965.EPI-04-0335 (Pubitemid 40270091)
28. Pearce C. L., Chung K., Pike M. C., Wu A. H., Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009 115 3 531 539 2-s2.0-60049086144 10.1002/cncr.23956
29. Pearce C. L., Near A. M., van den Berg D. J., Ramus S. J., Gentry-Maharaj A., Menon U., Gayther S. A., Anderson A. R., Edlund C. K., Wu A. H., Chen X., Beesley J., Webb P. M., Holt S. K., Chen C., Doherty J. A., Rossing M. A., Whittemore A. S., McGuire V., Dicioccio R. A., Goodman M. T., Lurie G., Carney M. E., Wilkens L. R., Ness R. B., Moysich K. B., Edwards R., Jennison E., Kjaer S. K., Hogdall E., Hogdall C. K., Goode E. L., Sellers T. A., Vierkant R. A., Cunningham J. M., Schildkraut J. M., Berchuck A., Moorman P. G., Iversen E. S., Cramer D. W., Terry K. L., Vitonis A. F., Titus-Ernstoff L., Song H., Pharoah P. D. P., Spurdle A. B., Anton-Culver H., Ziogas A., Brewster W., Galitovskiy V., Chenevix-Trench G., Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British Journal of Cancer 2009 100 2 412 420 2-s2.0-70449348238 10.1038/sj.bjc.6604820
30. Jiang D.-K., Wang W.-Z., Ren W.-H., Yao L., Peng B., Yu L., TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. Journal of Investigative Dermatology 2011 131 1 220 228 2-s2.0-78650301147 10.1038/jid.2010.270
31. Shen S.-Q., Jiang D.-K., Liu G.-Y., Chen F., Yu L., Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk. Molecular Biology Reports 2012 39 4 4683 4690 2-s2.0-84863089109 10.1007/s11033-011-1260- x
32. Mantel N., Haenszel W., Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959 22 4 719 748
33. DerSimonian R., Laird N., Meta-analysis in clinical trials. Controlled Clinical Trials 1986 7 3 177 188 2-s2.0-0022992740 (Pubitemid 17189972)
34. Egger M., Smith G. D., Schneider M., Minder C., Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997 315 7109 629 634 2-s2.0-0030922816 (Pubitemid 27387172)
35. Pedersen B. S., Konstantinopoulos P. A., Spillman M. A., De S., Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients. Genes Chromosomes and Cancer 2013 52 9 794 801 2-s2.0-84880506377 10.1002/gcc.22075
36. Cheng C. X., Xue M., Li K., Li W. S., Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy. Asian Pacific Journal of Cancer Prevention 2012 13 6 2541 2545 2-s2.0-84874064956 10.7314/APJCP.2012.13.6.2541
37. Gonzalez-Hormazabal P., Reyes J. M., Blanco R., Bravo T., Carrera I., Peralta O., Gomez F., Waugh E., Margarit S., Ibañez G., Santos J. L., Jara L., The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population. Molecular Biology Reports 2012 39 8 8091 8098 2-s2.0-84868657318 10.1007/s11033-012-1656-2
38. Clague J., Wilhoite G., Adamson A., Bailis A., Weitzel J. N., Neuhausen S. L., RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS ONE 2011 6 9 2-s2.0-80053259851 10.1371/journal.pone. 0025632 e25632
39. Drew Y., Mulligan E. A., Vong W.-T., Thomas H. D., Kahn S., Kyle S., Mukhopadhyay A., Los G., Hostomsky Z., Plummer E. R., Edmondson R. J., Curtin N. J., Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. Journal of the National Cancer Institute 2011 103 4 334 346 2-s2.0-79951887369 10.1093/jnci/djq509
40. Gottipati P., Vischioni B., Schultz N., Solomons J., Bryant H. E., Djureinovic T., Issaeva N., Sleeth K., Sharma R. A., Helleday T., Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination- defective cells. Cancer Research 2010 70 13 5389 5398 2-s2.0-77954374334 10.1158/0008-5472.CAN-09-4716
41. Jakubowska A., Gronwald J., Menkiszak J., Górski B., Huzarski T., Byrski T., Tołoczko-Grabarek A., Gilbert M., Edler L., Zapatka M., Eils R., Lubiński J., Scott R. J., Hamann U., BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Research and Treatment 2010 119 1 201 211 2-s2.0-72449175286 10.1007/s10549-009-0390-5
42. Danoy P., Sonoda E., Lathrop M., Takeda S., Matsuda F., A naturally occurring genetic variant of human XRCC2 (R188H) confers increased resistance to cisplatin-induced DNA damage. Biochemical and Biophysical Research Communications 2007 352 3 763 768 2-s2.0-33845309137 10.1016/j.bbrc.2006.11.083 (Pubitemid 44880321)